Publication | Open Access

Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB)

Breast OncologyOncologyMedicineGynecologyPhase Ii StudyBiomarker EvaluationBreast CancerLetrozole Versus LetrozoleCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyEndocrine-related Cancer